The discovery and development of a novel vaccine to protect against Neisseria meningitides serogroup B disease http://www.tandfonline.com/doi/pdf/10.4161/hv.34293

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 5-13

  Zlotnick, Gary W ^a   Jones, Thomas R ^a   Liberator, Paul ^a   Hao, Li ^a   Harris, Shannon ^a   McNeil, Lisa K ^a   Zhu, Duzhang ^a   Perez, John ^a   Eiden, Joseph ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Pfizervaccine Research   (United States)

Author keywords

Factor H binding protein; Neisseria meningitidis; Serogroup B; Serum bactericidal assay with human complement (hSBA); Vaccine

Indexed keywords

AMINO ACID; BACTERIAL VACCINE; MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; TRANSFERRIN BINDING PROTEIN; VIRULENCE FACTOR; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SAFETY; VACCINATION; YOUNG ADULT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGITIS, MENINGOCOCCAL; MICROBIOLOGY;

HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84922656137     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34293     Document Type: Review

References (38)

1. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7; PMID:6135869; http://dx.doi.org/10.1016/S0140-6736(83)90340-9
2. Milagres LG, Ramos SR, Sacchi CT, Melles CE, Vieira VS, Sato H, Brito GS, Moraes JC, Frasch CE. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994; 62:4419-24; PMID:7927704
3. Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, O'Hallahan JM, Oster P, Mulholland K, Martin DR. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009; 28:385-90; PMID:19384263; http://dx.doi.org/10.1097/INF.0b013e318195205e
4. Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6; PMID:1682541; http://dx.doi.org/10.1016/0140-6736(91)91961-S
5. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
6. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490-5; PMID:20962280; http://dx.doi.org/10.1073/pnas.1013758107
7. Danve B, Guinet F, Boutry E, Speck D, Cadoz M, Nassif X, et al. Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. In: Nassif MJQM, Taha MK, ed. Eleventh International Pathogenic Neisseria Conference. Paris, France, 1998; p53.
8. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67:5664-75; PMID:10531214
9. Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, Rosenstein NE, Perkins BA, Tondella ML, Mayer LW. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000; 182:1169-76; PMID:10979914; http://dx.doi.org/10.1086/315833
10. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004; 72:5955-62; PMID:15385499; http://dx.doi.org/10.1128/IAI.72.10.5955-5962.2004
11. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011; 29:4739-44; PMID:21571026; http://dx.doi.org/10.1016/j.vaccine.2011.04.092
12. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834-9; PMID:16825336; http://dx.doi.org/10.1073/pnas.0603940103
13. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-100; PMID:15039331; http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004
14. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006; 177:501-10; PMID:16785547; http://dx.doi.org/10.4049/jimmunol.177.1.501
15. Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008; 197:1053-61; PMID:18419542; http://dx.doi.org/10.1086/528994
16. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, Veggi D, Aricò B, Rappuoli R, Pizza M. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009; 77:292-9; PMID:18852235; http://dx.doi.org/10.1128/IAI.01071-08
17. Konar M, Granoff DM, Beernink PT. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis 2013; 208:627-36; PMID:23715659; http://dx.doi.org/10.1093/infdis/jit239
18. Giuntini S, Reason DC, Granoff DM. Complementmediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 2011; 79:3751-9; PMID:21708990; http://dx.doi.org/10.1128/IAI.05182-11
19. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086-93; PMID:20619376; http://dx.doi.org/10.1016/j.vaccine.2010.06.083
20. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379-89; PMID:19534597; http://dx.doi.org/10.1086/600141
21. Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009; 155:2873-83; PMID:19574307; http://dx.doi.org/10.1099/mic.0.029876-0
22. Hoiseth SK, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W, Abad R, Vazquez JA, Borrow R, Findlow J, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J 2013; 32:1096-101; PMID:23694830; http://dx.doi.org/10.1097/INF.0b013e31829aa63b
23. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013; 32:124-30; PMID:23588089; http://dx.doi.org/10.1016/j.vaccine.2013.03.063
24. Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010; 28:7667-75; PMID:20875489; http://dx.doi.org/10.1016/j.vaccine.2010.09.038
25. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B112-6; PMID:19464093; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
26. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-66; PMID:11287977
27. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009; 27:3417-21; PMID:19200847; http://dx.doi.org/10.1016/j.vaccine.2009.01.075
28. Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, Jones TR, Arora A. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, doseescalation phase 1 trial. Vaccine 2012; 30:6163-74; PMID:22871351; http://dx.doi.org/10.1016/j.vaccine.2012.07.065
29. Vesikari T, Diez-Domingo J, Ostergaard L, Beeslaar J, Eiden J, Jiang Q, et al. Safety and immunogenicity of an investigational meningococcal serogroup B bivalent rLP2086 vaccine in healthy adolescents. 32nd Annual ESPID Meeting. Dublin, Ireland, 2014.
30. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, et al.; 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597- 607; PMID:22569484; http://dx.doi.org/10.1016/S1473-3099(12)70087-7
31. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013; 32:364-71; PMID:23114369; http://dx.doi.org/10.1097/INF.0b013e31827b0d24
32. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012; 31:1061-8; PMID:22718089
33. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013; 31:1569-75; PMID:23352429; http://dx.doi.org/10.1016/j.vaccine.2013.01.021
34. Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, activecontrolled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 2012; 8:888-95; PMID:22832260; http://dx.doi.org/10.4161/hv.19983
35. Pfizer. Press release anouncing the designation of breakthrough therapy by the FDA to bivalent rLP2086, 2014
36. Pfizer. Press release anouncing the completion of the submission of the biological license application for the licensure of bivalent rLP2086, 2014
37. Bröker M. Indirect effects by meningococcal vaccines: herd protection versus herd immunity. Hum Vaccin 2011; 7:881-2; PMID:21785283; http://dx.doi.org/10.4161/hv.7.8.16273
38. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, et al. Vaccination against NeisZseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789- 99; PMID:12642606; http://dx.doi.org/10.1084/jem.20021911